Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Lags Revenue Estimates

分组1 - Agios Pharmaceuticals reported a quarterly loss of $1.69 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.58, and compared to a loss of $1.51 per share a year ago [1] - The company's revenues for the quarter were $8.62 million, missing the Zacks Consensus Estimate by 8.66%, and showing an increase from $6.71 million year-over-year [1] - Over the last four quarters, Agios Pharmaceuticals has surpassed consensus EPS estimates two times but has not beaten consensus revenue estimates [1] 分组2 - The stock has gained approximately 108.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 15.8% [2] - The current consensus EPS estimate for the upcoming quarter is -$0.35 on revenues of $10.89 million, and for the current fiscal year, it is -$2.15 on revenues of $41.02 million [4] - The Medical - Products industry, to which Agios Pharmaceuticals belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [5]